BCL2L1 and acute myeloid leukemia: Despite having a half-life in plasma of approximately 1.5 hours, MYCMI-7 treatment reduced tumor volume significantly in all three models and increased overall survival in two of three models (Figs. 7, 8), with exception of MYC/BCL-XL–driven AML.